Clinical Research Directory
Browse clinical research sites, groups, and studies.
Terazosin for Dementia With Lewy Bodies
Sponsor: Qiang Zhang
Summary
The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.
Official title: a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies
Key Details
Gender
All
Age Range
0 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2027-10
Completion Date
2030-12
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
Terazosin Hydrochloride
In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
Placebo
In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
Locations (1)
University of Iowa
Iowa City, Iowa, United States